"In the studies conducted by our group, the use of inhaled nitric oxide resulted in a statistically significant improvement in both the short- and long-term pulmonary outcome for pre-term infants at high risk for BPD," commented Roberta A. Ballard, MD, Professor of Pediatrics, University of California, San Francisco, and Emeritus Professor of Pediatrics and Obstetrics and Gynecology, University of Pennsylvania. "However, those studies administered a higher dose of nitric oxide to premature infants with an established higher risk of BPD. I believe the risk-dose equation may have contributed to the results of this trial, and anticipate that additional studies will provide clarification." Dr. Ballard has published more than 60 papers in peer-review journals, and is active in the research to prevent BPD in premature infants with respiratory problems.
Ikaria Holdings, Inc. currently is analyzing the data and conducting additional research to better understand the results and determine opportunities for future research into the use of nitric oxide in different doses or specific patient sub-groups for the treatment of BPD in premature infants. Nitric oxide for inhalation should not be used routinely as a preventive treatment in pre-term infants for the prevention of BPD.
About Ikaria Holdings, Inc.
Ikaria Holdings, Inc. is a fully integrated biotherapeutics company
focused on the development and commercialization of innovative
pharmaceuticals, biologic messengers and drug-device combinations for
hospitalized, critically ill patients. The company's lead product,
INOmax(R) (nitric oxid
|SOURCE Ikaria Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved